Why the study?
Whether the microglial-vascular interface in the brain is affected during heart failure remains unknown.
Does AT1aR blockade prevent microglia-vascular interaction changes and neuroinflammation in the hippocampus of rats with heart failure?
Does AT1aR blockade prevent microglia-vascular interaction changes and neuroinflammation in the hippocampus of rats with heart failure?
Answers are grounded in this paper and cite their sources.
Angiotensin II-AT1a receptor signaling drives the recruitment of microglia to the perivascular space in the hippocampus of heart failure rats, contributing to neuroinflammation that can be reversed with losartan.
Activation of microglia, the resident immune cells of the central nervous system, leading to the subsequent release of pro-inflammatory cytokines, has been linked to cardiac remodeling, autonomic disbalance, and cognitive deficits in heart failure (HF). While previous studies emphasized the role of hippocampal Angiotensin II (AngII) signaling in HF-induced microglial activation, unanswered mechanistic questions persist. Evidence suggests significant interactions between microglia and local microvasculature, potentially affecting blood-brain barrier integrity and cerebral blood flow regulation. Still, whether the microglial-vascular interface is affected in the brain during HF remains unknow. Using a well-established ischemic HF rat model, we demonstrate increased vessel-associated microglia (VAM) in HF rat hippocampi, which showed heightened expression of AngII AT1a receptors. Acute AngII administration to sham rats induced microglia recruitment to the perivascular space, along with increased expression of TNFa. Conversely, administering an AT1aR blocker to HF rats prevented the recruitment of microglia to the perivascular space, normalizing their levels to those in healthy rats. These results highlight the critical importance of a rather understudied phenomenon (i.e., microglia-vascular interactions in the brain) in the context of the pathophysiology of a highly prevalent cardiovascular disease, and unveil novel potential therapeutic avenues aimed at mitigating neuroinflammation in cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Althammer et al. (2023) studied Heart Failure (n=64). Losartan vs. Untreated heart failure (HF) control was evaluated on Proportion of vessel-associated microglia (VAM).
Synapse has enriched 10 related papers. Consider them for comparative context: